Research graph
References from Melatonin potentiates the antineoplastic effects of venetoclax in acute myeloid leukemia cells. Local targets link to admitted publications; unresolved targets remain external evidence.
Targeting acute myeloid leukemia with venetoclax; biomarkers for sensitivity and rationale for venetoclax-based combination therapies
10.3390/cancers14143456 · 2022 · External reference
The spectrum of venetoclax-based treatments in acute myeloid leukemia
10.3390/cancers18081201 · 2026 · External reference
Venetoclax-based combinations in acute myeloid leukemia: current evidence and future directions
10.3389/fonc.2020.562558 · 2020 · External reference
Melatonin as a regulator of apoptosis in leukaemia: molecular mechanism and therapeutic perspectives
10.3389/fphar.2023.1224151 · 2023 · External reference
Promising antineoplastic actions of melatonin
10.3389/fphar.2018.01086 · 2018 · External reference
Inhibition of proliferation and induction of apoptosis by melatonin in human myeloid HL-60 cells
10.1111/j.1600-079x.2006.00392.x · 2007 · External reference
Melatonin inhibits MLL-rearranged leukemia via RBFOX3/hTERT and NF-kappaB/COX-2 signaling pathways
10.1016/j.canlet.2018.11.037 · 2019 · External reference
[Melatonin enhances the effect of ABT-737 in acute monocytic leukemia THP-1 cells]
10.1134/s002689332401014x · 2024 · External reference
Effect of melatonin on the cytotoxicity of chemotherapeutic drugs in human leukemia cells
2011 · External reference
Metabolic reprogramming represents a targetable mechanism to overcome acquired resistance to venetoclax in acute myeloid leukemia
10.1016/j.bbadis.2025.168065 · 2026 · External reference
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
10.1038/s41392-021-00870-3 · 2022 · External reference
Melatonin combined with antineoplastic drugs or natural products for cancer treatment: an update
10.1016/j.crphar.2025.100239 · 2025 · External reference
Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review
10.1517/14728222.2013.834890 · 2013 · External reference
Adjuvant chemotherapy with melatonin for targeting human cancers: a review
10.1002/jcp.27259 · 2019 · External reference
Melatonin and cancer: towards a time-sensitive oncological adjunct
10.1016/j.clinsp.2025.100834 · 2025 · External reference
Adjuvant chemotherapy with melatonin for targeting human cancers: a review
10.1002/jcp.27259 · ExternalCitation · doi-reference
Metabolic reprogramming represents a targetable mechanism to overcome acquired resistance to venetoclax in acute myeloid leukemia
10.1016/j.bbadis.2025.168065 · ExternalCitation · doi-reference
Melatonin inhibits MLL-rearranged leukemia via RBFOX3/hTERT and NF-kappaB/COX-2 signaling pathways
10.1016/j.canlet.2018.11.037 · ExternalCitation · doi-reference
Melatonin and cancer: towards a time-sensitive oncological adjunct
10.1016/j.clinsp.2025.100834 · ExternalCitation · doi-reference
Melatonin combined with antineoplastic drugs or natural products for cancer treatment: an update
10.1016/j.crphar.2025.100239 · ExternalCitation · doi-reference
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
10.1038/s41392-021-00870-3 · ExternalCitation · doi-reference
Inhibition of proliferation and induction of apoptosis by melatonin in human myeloid HL-60 cells
10.1111/j.1600-079x.2006.00392.x · ExternalCitation · doi-reference
[Melatonin enhances the effect of ABT-737 in acute monocytic leukemia THP-1 cells]
10.1134/s002689332401014x · ExternalCitation · doi-reference
Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review
10.1517/14728222.2013.834890 · ExternalCitation · doi-reference
Venetoclax-based combinations in acute myeloid leukemia: current evidence and future directions
10.3389/fonc.2020.562558 · ExternalCitation · doi-reference
Promising antineoplastic actions of melatonin
10.3389/fphar.2018.01086 · ExternalCitation · doi-reference
Melatonin as a regulator of apoptosis in leukaemia: molecular mechanism and therapeutic perspectives
10.3389/fphar.2023.1224151 · ExternalCitation · doi-reference
Targeting acute myeloid leukemia with venetoclax; biomarkers for sensitivity and rationale for venetoclax-based combination therapies
10.3390/cancers14143456 · ExternalCitation · doi-reference
The spectrum of venetoclax-based treatments in acute myeloid leukemia
10.3390/cancers18081201 · ExternalCitation · doi-reference
